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Persistent stromal fibroblast activation is
present in chronic tendinopathy
Stephanie G. Dakin1*, Christopher D. Buckley2, Mohammad Hussein Al-Mossawi1, Robert Hedley1,
Fernando O. Martinez1,3, Kim Wheway1, Bridget Watkins1 and Andrew J. Carr1
Abstract
Background: Growing evidence supports a key role for inflammation in the onset and progression of
tendinopathy. However, the effect of the inflammatory infiltrate on tendon cells is poorly understood.
Methods: We investigated stromal fibroblast activation signatures in tissues and cells from patients with
tendinopathy. Diseased tendons were collected from well-phenotyped patient cohorts with supraspinatus
tendinopathy before and after sub-acromial decompression treatment. Healthy tendons were collected from
patients undergoing shoulder stabilisation or anterior cruciate ligament repair. Stromal fibroblast activation markers
including podoplanin (PDPN), CD106 (VCAM-1) and CD248 were investigated by immunostaining, flow cytometry
and RT-qPCR.
Results: PDPN, CD248 and CD106 were increased in diseased compared to healthy tendon tissues. This stromal
fibroblast activation signature persisted in tendon biopsies in patients at 2–4 years post treatment. PDPN, CD248
and CD106 were increased in diseased compared to healthy tendon cells. IL-1β treatment induced PDPN and
CD106 but not CD248. IL-1β treatment induced NF-κB target genes in healthy cells, which gradually declined
following replacement with cytokine-free medium, whilst PDPN and CD106 remained above pre-stimulated levels.
IL-1β-treated diseased cells had more profound induction of PDPN and CD106 and sustained expression of IL6 and
IL8 mRNA compared to IL-1β-treated healthy cells.
Conclusions: We conclude that stromal fibroblast activation markers are increased and persist in diseased
compared to healthy tendon tissues and cells. Diseased tendon cells have distinct stromal fibroblast populations. IL-
1β treatment induced persistent stromal fibroblast activation which was more profound in diseased cells. Persistent
stromal fibroblast activation may be implicated in the development of chronic inflammation and recurrent
tendinopathy. Targeting this stromal fibroblast activation signature is a potential therapeutic strategy.
Keywords: Tendon, Tendinopathy, Inflammation, Stromal fibroblast
Background
Musculoskeletal diseases account for 5 of the top 15
causes of years lived with disease in well-resourced
health systems [1]. Soft-tissue pathologic conditions such
as tendinopathy are a common cause of pain and loss of
function and an important and increasing component of
health expenditure in ageing societies [2]. Diseased ten-
dons heal by forming a repair scar; however, the normal
architecture, composition, and tissue function are not
fully restored, increasing susceptibility to chronic injury.
The aetiology of tendinopathy is complex and multi-
factorial, encompassing the effects of repetitive damage,
daily exercise, ageing and genetic factors [3, 4]. Growing
evidence supports the contribution of inflammation to
the onset and progression of tendinopathy [5–8]; how-
ever, the mechanisms underpinning the development of
chronic tendon inflammation are poorly understood.
Recent work highlights the complex activation states
of immune cells including macrophages populating
diseased human shoulder tendons [8]. Investigation of
inflammation activation pathways in cultured stromal
cells from diseased human tendons has revealed that
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diseased stromal cells may be primed for inflammation
[8]. However, the mechanism of this priming and the
relative contribution of tendon stromal cells to sustain-
ing chronic inflammation are unknown.
Recent studies support the importance of tissue micro-
environments and the innate immune response in per-
petuating the inflammatory process. Non-myeloid/
non-lymphoid populations such as resident stromal fi-
broblasts are known to play a prominent role in the
generation and maintenance of chronic synovial inflam-
mation [9, 10]. Stromal fibroblast activation is reported
in rheumatoid arthritis (RA) in which resident stromal
cells fail to switch off their inflammatory programme.
Phenotypic alterations in RA synovial fibroblasts play an
important role in the switch from resolving to persistent
disease [11, 12].
The process by which fibroblasts produce cytokines,
chemokines, prostanoids and extracellular matrix pro-
teins is termed “fibroblast activation”. Activated fibro-
blasts are found in damaged, inflamed or healing tissues
and promote the retention of immune cells and regulate
their behaviour [12]. Previously identified stromal fibro-
blast activation markers in the synovium in RA include
podoplanin (PDPN), CD106 (VCAM-1) and CD248
(tumour endothelial marker-1/endosialin). PDPN is a
transmembrane glycoprotein implicated in the invasive-
ness of cancer metastasis and CD106 functions as a cell
adhesion molecule [13]. CD248 is a transmembrane
receptor with ligands that include collagen 1 and fibro-
nectin [14]. CD248 expression is up-regulated by inflam-
mation, fibrosis, angiogenesis and malignancy [15, 16].
These stromal fibroblast activation markers have been
identified in different locations of the synovium in RA.
PDPN and CD106 are located in the synovial lining and
CD248 in the sub-lining layer, and they are thought to
represent distinct fibroblast subsets [12, 13].
In this study, we identified the potential role of tendon
stromal fibroblasts (resident fibroblasts populating
tendons) as an important tissue-resident population im-
plicated in the development of chronic tendon inflam-
mation. We studied supraspinatus tendon tissues from a
well-phenotyped longitudinal cohort of patients with
symptoms pre and post treatment. We characterised
distinct stromal fibroblast activation signatures in healthy,
diseased and post-treatment tendon tissues. As IL-1β
induces NF-κB target genes known to be highly expressed
in early-stage tendinopathy [8], we further investigated if
IL-1β treatment of cultured tendon cells induces persist-
ent stromal fibroblast activation, and if this response
differs between healthy and diseased cells. We hypothe-
sized that diseased tendons express stromal fibroblast
activation markers and that IL-1β-treated diseased tendon
cells show profound induction of PDPN, CD106 and
NF-κB target genes.
Methods
Collection of tendon tissues
Patients were recruited from shoulder referral clinics
where the structural integrity of the rotator cuff was
determined by ultrasound. Patients presenting to the
referral shoulder clinic had not responded to non-
surgical treatment, including a course of physical
therapy and glucocorticoid injections into the sub-
acromial space, and had experienced pain for a mini-
mum of 3 months. Patients completed the Oxford
shoulder score (OSS), a validated and widely used
clinical outcome measure scoring from 0 (severe dis-
ease) to 48 (normal function) [17]. Samples of healthy
supraspinatus tendons (n = 5) were collected intra-
operatively from patients undergoing shoulder surgery
for post-traumatic instability. These biopsies were col-
lected from male and female patients (ages 20–30
years, mean 23 ± 3.8 years) who had intact supraspi-
natus tendons on ultrasound, which was confirmed at
surgery. Healthy subscapularis tendons (n = 4) were
collected from male or female patients undergoing
shoulder surgery for post-traumatic instability (ages
61–77 years, mean 66 ± 8 years). Body mass index
(BMI) in the patients with healthy shoulder tendons
was 24.5 (±1.5).
Diseased supraspinatus tendons were collected from
male and female patients undergoing sub-acromial
decompression surgery (biopsies were collected from
six patients) or surgical debridement of a supraspina-
tus tendon tear (n = 9). Tendon tear sizes were classi-
fied as small (≤1 cm), medium (>1 and ≤3 cm), large
(>3 and ≤5 cm) and massive (>5 cm in anterior-
posterior length) [18]. Patients with diseased supraspi-
natus tendons were aged between 44 and 75 years
(mean 55 ± 18.3 years). BMI in the patients with dis-
eased tendons was not significantly different to that
in the healthy group (27.8 ± 1.2).
Torn tendons were collected under research ethics
from the Oxford Musculoskeletal Biobank (09/H0606/
11). Biopsies were also taken from patients between 2
and 4 years after undergoing sub-acromial decompres-
sion surgery, in whom pain had resolved completely
(n = 6) or pain persisted (n = 5). Post-treatment biopsies
were collected by percutaneous ultrasound-guided bi-
opsy under local anaesthesia. The biopsy specimen was
taken using a Trucut needle 5–10 mm posterior to the
anterior edge of the supraspinatus tendon. This validated
biopsy technique is described in detail elsewhere [19].
Exclusion criteria for all patients in this study included
previous shoulder surgery, other pathologic conditions
of the shoulder or acute trauma, rheumatoid arthritis
and systemic inflammatory disease.
For cell experiments, healthy hamstring tendons were
collected from 10 male and female patients undergoing
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surgical reconstruction of their anterior cruciate liga-
ment. All patients were aged between 18 and 48 years
(mean 25.5 ± 11 years). BMI in the patients with healthy
hamstring tendons was 24.9 (±2.1) and was not signifi-
cantly different to that in the diseased patient group.
Hamstring tendons were collected under research ethics
from the Oxford Musculoskeletal Biobank (09/H0606/
11). Hamstring tendons were immediately placed in Dul-
becco’s minimum essential medium (DMEM)/F12
(Lonza) and processed in tissue culture to isolate the
tendon-derived stromal cells.
Processing of tendon samples
Immunohistochemistry analysis and immunofluorescence
Healthy and diseased supraspinatus tendons were
immersed in 10% buffered formalin for 0.5 mm/hour.
After fixation, tendons were processed using a Leica
ASP300S tissue processor and embedded in paraffin
wax. Tissues were sectioned at 4 μm using a rotary
RM2135 microtome (Leica Microsystems Ltd.) onto ad-
hesive glass slides and baked at 60 °C for 30 minutes
and 37 °C for 60 minutes.
Histological assessment of healthy and diseased
supraspinatus tendons
Histological assessment of tendons collected from the
study cohort was performed on hematoxylin-and-eosin-
stained sections using the Bonar scoring system (0–12)
that evaluates tissue structure [20]. Healthy supraspinatus
tendons exhibited a more normal tissue architecture (me-
dian 2, interquartile range 1–2) compared to tendinopathic
(median 7, interquartile range 6–8) and torn supraspinatus
tendons (median 10, interquartile range 8.25–10).
Gene expression
Samples of healthy subscapularis and diseased supraspi-
natus tendons were immediately snap-frozen in liquid
nitrogen and stored at −80 °C until RNA extraction.
Immunohistochemistry and immunofluorescence for
identification of stromal fibroblast activation markers in
tendons
For antigen retrieval, slides were baked at 60 °C for
60 minutes, and tissue sections subjected to deparaffini-
zation and target retrieval steps (heat-mediated antigen
retrieval at high pH) using an automated PT Link
(Dako). For single-staining immunohistochemistry ana-
lysis, antibody staining was performed using the EnVi-
sion FLEX visualization system with an Autostainer Link
48 (Dako). Antibody binding was visualized using FLEX
3,3’-diaminobenzidine (DAB) substrate working solution
and hematoxylin counterstain (Dako) using the recom-
mended manufacturer protocols. After staining, slides
were taken through graded alcohol and xylene and
mounted in Pertex mounting medium (Histolab). For
multiple antibody immunofluorescence staining and
image acquisition, protocols were adapted from Dakin et
al., 2015 [8], using the primary antibodies listed in
Table 1. Sections of diseased rheumatoid synovium were
used as positive controls to confirm immunostaining for
PDPN and CD248. Isotype control antibodies were a
cocktail of mouse immunoglobulin G (IgG1), IgG2a,
IgG2b, IgG3, and IgM (Dako) and rabbit immunoglobulin
fraction of serum from non-immunized rabbits, solid-
phase absorbed (Dako).
Isolation of tendon-derived stromal cells
Tendon cells were isolated from healthy hamstring and
diseased supraspinatus tendons. Diseased tendon cells
were isolated from patients with small to medium ten-
don tears (<3 cm in length). Small to medium tendon
tears are known to express genes and proteins induced
by interferon and NFκB inflammation activation path-
ways [8]. Tendons were cut into 2-mm3 explants and
incubated in DMEM/F12 (Lonza) containing 50% fetal calf
serum (FCS; Labtech) and 1% penicillin-streptomycin
(Lonza). Fresh medium was replaced every 4 days, and
cells were allowed to grow out from explants over time in
a tissue culture incubator at 37 °C and 5% CO2. Once cells
were confluent, explants were removed and media re-
placed with DMEM/F12 containing 10% FCS and 1%
penicillin-streptomycin. Cells between passages 1 and 3
were used for all experiments.
Treatment of tendon-derived stromal cells with IL-1β
Tendon-derived stromal cells isolated from healthy ham-
string and diseased supraspinatus were seeded at a dens-
ity of 30,000 cells per well in a 12-well plate (mRNA) or
60,000 cells in a 6-well plate (flow cytometry). Cells were
allowed to reach 80% confluence prior to stimulation
with IL-1β (10 ng/mL-1). Tendon cells were incubated in
DMEM F12 medium (Lonza) containing 1% heat-
Table 1 Primary antibodies used for immunohistochemistry analysis and immunofluorescence
Antibody Clone Isotype Species Dilution
Podoplanin (PDPN) Abcam Ab10288 18H5 IgG1 Mouse 1:100
CD248 (TEM1) Abcam Ab204914 EPR17081 IgG Rabbit monoclonal 1:1000
CD106 (VCAM-1) LS-Biosciences LS_C313019 IgG Rabbit polyclonal 1:100
TLR4 Abcam Ab22048 76B357.1 IgG2b Mouse 1:200
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inactivated human serum (Sigma). Medium containing
sterile filtered 0.1% endotoxin-free BSA (Sigma) diluted
in PBS was used for vehicle-only controls. After IL-1β or
vehicle treatment, cells were incubated for 24 hours at
37 °C and 5% CO2 until harvest of the lysate for mRNA
or flow cytometry.
Extraction of RNA from tendons
Protocols for RNA extraction from healthy and dis-
eased tendon tissues and cells, complementary DNA
synthesis and quantitative polymerase chain reaction
are described elsewhere [8]. cDNA, 2 μL, was used in
a 10-μL qPCR volume with Fast SYBR Green Master
Mix (Applied Biosystems) and diluted Qiagen vali-
dated human primers including PDPN (QT01015084),
CD248 (QT00216356), CD106 (QT00018347) β-actin
(QT00095431) and glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) (QT00079247). Duplicate reac-
tions for each gene were run on a ViiA7 qPCR
machine (Applied Biosystems) and results were calcu-
lated using the DDCt method using reference genes
for human β-actin and GAPDH. Results were consist-
ent using these reference genes and data are shown
normalized to β-actin.
Flow cytometry
After harvest, tendon cells were washed twice in cell
staining buffer (CSB) (BioLegend) and blocked for
15 minutes at room temperature (RT) in 20% human
FcR blocking reagent (Miltenyi Biotech) diluted in CSB.
All dead cells were excluded from analysis using fixable
viability dye ef780 (1:1000 dilution) (eBioscience). Cells
were stained in a buffer containing 20% FcR blocking
reagent diluted in CSB at RT for 30 minutes. Antibody
and isotype cocktails were prepared as indicated in
Table 2. After washing, cells were fixed using Cytofix
fixation buffer (BD Biosciences) for 20 minutes at RT.
Flow cytometry was performed on a BD LSR Fortessa
instrument calibrated daily with BD cytometer setup
and tracking beads. Analysis of data was carried out
using FlowJo software (Treestar).
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 6 (GraphPad Software). Normality was tested
using the Shapiro-Wilk normality test. The Kruskal-
Wallis test followed by pairwise the post hoc Mann-
Whitney U test was used to compare PDPN, CD248 and
CD106 mRNA expression in healthy, diseased and post-
treatment tendons. The pairwise Mann-Whitney U test
was used to test for differences in gene and protein
expression of PDPN, CD106 and CD248 between vehicle
and IL-1β-treated healthy and diseased tendon cells. The
pairwise Mann-Whitney U test was used to test for
differences between mRNA expression of PDPN, CD106
and NF-κB target genes in cytokine-treated healthy and
diseased tendon cells. P < 0.05 was considered statisti-
cally significant.
Results
Diseased tendon tissues express stromal fibroblast
activation markers
Markers of stromal fibroblast activation including
PDPN, CD248 and CD106 have not been investi-
gated in healthy and diseased tendon tissues. Post-
treatment supraspinatus tendon biopsy samples were
collected from patients 2–4 years after surgical sub-
acromial decompression (SAD) treatment. This post-
treatment patient group consisted of six patients
who were asymptomatic after treatment and five
who remained symptomatic.
Diseased supraspinatus tendons had significantly in-
creased PDPN, CD248 and CD106 mRNA compared
to healthy subscapularis tendons (Fig. 1a) (p = 0.001,
p = 0.003 and p = 0.0007, respectively). This stromal
activation signature was also present in supraspinatus
Table 2 Antibodies used for flow cytometry
Antibody Catalogue number Clone
PDPN Alexa Fluor 488 anti-human 337005 BioLegend NC08
Alexa Fluor 488 Rat IgG2aκ isotype 400525 BioLegend RTK2758
CD248 Alexa Fluor 647 anti-human 564994 BD Biosciences B1/35
Alexa Fluor 647 mouse IgG1κ isotype 557714 BD Biosciences MOPC-21
CD106 PE anti-human 305806 BioLegend STA
PE mouse IgG1κ isotype 400112 BioLegend MOPC-21
CD34 PerCP/Cy5.5 anti-human 343521 BioLegend 581
PerCP/Cy5.5 mouse IgG1κ isotype 400149 BioLegend MOPC-21
CD45 BV605 anti-human 304041 BioLegend H130
BV605 mouse IgG1κ isotype 400161 BioLegend MOPC-21
All antibodies were diluted 1:50 for staining
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tendon biopsies from post-treatment patients (p = 0.0015,
p = 0.0015 and p = 0.006, respectively). Diseased and post-
treatment supraspinatus tendons had increased immuno-
positive staining for PDPN, CD248 and CD106 compared
to healthy supraspinatus tendons (Fig. 1b). Co-staining
revealed co-localization of PDPN, CD106 and toll-like
receptor 4 (TLR4) in diseased tendons (Fig. 1c). CD248+
cells were closely associated with clusters of PDPN+ cells.
However, only a few cells expressed both PDPN and
CD248 (Fig. 1d).
Markers of stromal fibroblast activation are increased in
diseased compared to healthy tendon-derived stromal
cells
Markers of stromal fibroblast activation identified in dis-
eased human tendons were further studied in healthy
Fig. 1 Diseased tendon tissues express markers of stromal fibroblast activation. amRNA expression of stromal fibroblast activation markers podoplanin
(PDPN), CD248 and CD106 in healthy subscapularis tendons and diseased and post-treatment supraspinatus tendons. Bar shows median values. Statistically
significant differences were calculated using the Kruskal-Wallis test with the pairwise post hoc Mann-Whitney U test; **p< 0.01, ***p< 0.001. b Representative
images of 3,3’-diaminobenzidine immunostaining (brown) for PDPN, CD248 and CD106 in healthy, diseased and post-treatment supraspinatus tendons.
Nuclear counterstain is haematoxylin. Scale bar 50 μm. c and d Representative immunofluorescence images of sections of diseased supraspinatus tendons
stained for markers of stromal activation (PDPN, green; CD248 and CD106, purple) and toll-like receptor 4 (TLR4) (red). Cyan represents POPO-1 nuclear
counterstain. Scale bar 20 μm
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and diseased tendon-derived stromal cells to investigate
the effects of cytokine treatment on stromal fibroblast
activation in vitro. Diseased cells had increased PDPN
mRNA compared to healthy cells under baseline un-
stimulated conditions (medium containing vehicle only)
(p = 0.008) (Fig. 2a). IL-1β treatment of healthy and
diseased cells for 24 hours further induced PDPN (p =
0.008). Induction of PDPN was more profound in IL-1β-
treated diseased compared to IL-1β-treated healthy cells
(p = 0.03). PDPN protein was increased in diseased
compared to healthy cells under baseline unstimulated
conditions (p = 0.008) (Fig. 2b and c). IL-1β treatment of
healthy and diseased cells further induced PDPN (p =
0.008). Induction of PDPN was more profound in IL-1β-
treated diseased compared to IL-1β-treated healthy cells
(p = 0.008).
Diseased cells had increased CD106 mRNA compared
to healthy cells under baseline unstimulated conditions
(p = 0.03) (Fig. 3a). IL-1β treatment of diseased cells fur-
ther induced CD106 (p = 0.008). Induction of CD106
was more profound in IL-1β-treated diseased compared
to IL-1β-treated healthy cells (p = 0.008). CD106 protein
was increased in diseased compared to healthy cells
under baseline unstimulated conditions (p = 0.03) (Fig. 3b
and c). IL-1β treatment of healthy and diseased cells
further induced CD106 (p = 0.008).
Diseased cells also had increased CD248 mRNA
compared to healthy cells under baseline unstimulated
conditions (p = 0.03) (Fig. 4a). IL-1β treatment did not
significantly attenuate CD248 mRNA. CD248 protein
was increased in diseased compared to healthy cells
under baseline unstimulated conditions (p = 0.008)
(Fig. 4b and c). IL-1β treatment of diseased cells reduced
CD248 (p = 0.008).
Inflammation induces persistent stromal activation in
tendon-derived stromal cells
Having identified that stromal fibroblast activation
markers were present in diseased tendon tissues 2–4
years after treatment, we sought to investigate if IL-1β
treatment induces stromal fibroblast “memory” in
healthy and diseased tendon cells in vitro. Diseased cells
had increased PDPN and CD106 mRNA compared to
healthy cells under baseline unstimulated conditions
(p = 0.03 respectively). IL-1β treatment for 24 hours in-
duced PDPN and CD106, induction was more profound
in diseased compared to healthy cells (p = 0.03) (Fig. 5 a
and b). In healthy cells PDPN and CD106 mRNA
remained elevated beyond pre-stimulated levels follow-
ing replacement with cytokine-free medium for 4 days
(p = 0.03). In diseased cells, PDPN returned to pre-
stimulated levels; however, CD106 remained elevated be-
yond pre-stimulated levels following replacement with
cytokine-free medium for 4 days (p = 0.03).
IL-1β treatment of healthy and diseased tendon cells
also induced NF-κB target genes including IL6, IL8,
Fig. 2 Expression of podoplanin (PDPN) mRNA and protein in healthy and diseased tendon cells after IL-1β treatment. Tendon cells were derived
from healthy hamstring (n = 5 donors) and diseased supraspinatus tendons (n = 5 donors). Tendon cells were treated with medium containing
vehicle only or IL-1β (10 ng/ml-1) for 24 hours. PDPN mRNA expression (a) and PDPN protein (b) are shown in healthy and diseased tendon cells
after vehicle and IL-1β treatments. c Representative fluorescence-activated cell sorting (FACS) contour plots for PDPN from healthy and diseased
tendon cells after vehicle and IL-1β treatments gated on CD45-CD34- cells. Bar shows median values. Statistically significant differences were
calculated using the Kruskal-Wallis test with the pairwise post hoc Mann-Whitney U test; *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 3 Expression of CD106 mRNA and protein in healthy and diseased tendon cells after IL-1β treatment. Tendon cells were derived from healthy
hamstring (n = 5 donors) and diseased supraspinatus tendons (n = 5 donors). Tendon cells were treated with medium containing vehicle only or
IL-1β (10 ng/ml-1) for 24 hours. CD106 mRNA expression (a) and CD106 protein (b) are shown in healthy and diseased tendon cells after vehicle
and IL-1β treatments. c Representative fluorescence-activated cell sorting (FACS) contour plots for CD106 from healthy and diseased tendon cells
after vehicle and IL-1β treatments gated on CD45-CD34- cells. Bar shows median values. Statistically significant differences were calculated using
the Kruskal-Wallis test with the pairwise post hoc Mann-Whitney U test; *p < 0.05, **p < 0.01
Fig. 4 Expression of CD248 mRNA and protein in healthy and diseased tendon cells after IL-1β treatment. Tendon cells were derived from healthy
hamstring (n = 5 donors) and diseased supraspinatus tendons (n = 5 donors). Tendon cells were treated with medium containing vehicle only or IL-1β
(10 ng/mL-1) for 24 hours. CD248 mRNA (a) and CD248 protein (b) are shown in healthy and diseased tendon cells after vehicle and IL-1β treatments.
c Representative fluorescence-activated cell sorting (FACS) contour plots for CD106 from healthy and diseased tendon cells after vehicle and IL-1β
treatments gated on CD45-CD34- cells. Bar shows median values. Statistically significant differences were calculated using the Kruskal-Wallis test with
the pairwise post hoc Mann-Whitney U test; *p < 0.05, **p < 0.01, ***p < 0.001
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STAT-1 and IFIT1 (Fig. 5c-f). In healthy cells there was a
gradual decline in these pro-inflammatory genes follow-
ing replacement with cytokine-free medium. IL-1β-
treated diseased cells had a more sustained induction of
IL6 and IL8 compared to IL-1β-treated healthy cells
between 2 and 4 days following replacement with
cytokine-free medium (p = 0.03 for each respective time
point) (Fig. 5c and d).
Positive and isotype controls for immunostaining
Sections of diseased rheumatoid synovium were used as
positive controls to confirm immunostaining for PDPN
and CD248 (Fig. 6). Isotype control staining was
performed using sections of diseased supraspinatus ten-
dons (Fig. 7a and b).
Discussion
The effect of the inflammatory process on resident
tendon stromal cells is poorly understood. This study
provides new insights into the pathogenesis of diseases
affecting these musculoskeletal soft tissues. We identi-
fied a mechanism whereby diseased tendon tissues and
cells become activated after exposure to an inflammatory
stimulus, which induces a sustained change in their
phenotype whereby cells express markers of stromal
fibroblast activation including PDPN, CD106 and
Fig. 5 Effects of IL-1β on podoplanin (PDPN), CD106 and NF-κB genes in healthy and diseased tendon cells over time. Tendon cells were derived
from healthy hamstring (n = 4 donors) and diseased supraspinatus tendons (n = 4 donors). Cell lysates were sequentially harvested at day 0
(pre-stimulation), day 1 (24 hours after IL-1β treatment, 10 ng/mL-1) and days 2, 3, 4 and 5 when cells were incubated in cytokine-free medium
containing vehicle only. mRNA expression is shown for PDPN (a), CD106 (b), IL6 (c), IL8 (d), STAT-1 (e) and IFIT1 (f). Data are mean ± SEM. Statistically
significant differences were calculated using the pairwise Mann-Whitney U test for healthy and diseased cells at each time point; *p < 0.05
Fig. 6 Positive control staining of rheumatoid synovium for markers of stromal fibroblast activation. Representative confocal immunofluorescence
images show podoplanin (PDPN) (green), CD248 (purple) and toll-like receptor 4 (TLR4) (red). Cyan represents POPO-1 nuclear counterstain. Scale
bar 20 μm.
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CD248. This longitudinal cohort study of phenotyped
human tendon tissues collected pre and post treatment
revealed that this stromal fibroblast activation signature
persisted in tendon biopsies from patients who were up
to 4 years post-treatment. Stromal activation and its
persistence in vivo were further confirmed by IL-1β
treatment of cultured tendon stromal cells in vitro.
Stromal fibroblast activation is a feature of the syno-
vium in RA, where markers including PDPN, CD106
and CD248 have been identified [11, 12]. To our know-
ledge this is the first study to identify these stromal
fibroblast activation markers in non-immune mediated
musculoskeletal disease. IL-1β treatment of cultured
tendon stromal cells induced markers of fibroblast acti-
vation including PDPN and CD106 but not CD248, sug-
gesting distinct stromal responses in diseased tendons.
In support of this, immunostaining of diseased tendons
revealed co-localization of PDPN, CD106 and TLR4,
suggestive of a pro-inflammatory tendon cell phenotype.
CD248+ cells were closely associated with clusters of
PDPN+ cells, but only a small number of cells expressed
both PDPN and CD248 in diseased tendons. In RA,
PDPN and CD106 are located in the synovial lining, and
CD248 is located in the sub-lining layer, and these are
thought to represent distinct fibroblast subsets [12, 13].
PDPN-expressing fibroblasts possess a pro-inflammatory
phenotype in RA and malignancy [21, 22]. CD248-
expressing fibroblasts have also been identified in hep-
atic and renal fibrosis, representing a reparative popula-
tion [23].
Cancer-associated fibroblasts are known to maintain a
state of permanent activation after the effects of the ini-
tiating stimulus subsides. This activated phenotype per-
sists until cell senescence [24]. Cells populating diseased
tendons are known to be apoptotic and senescent [5].
Furthermore, turnover of tendon collagenous matrix
components is known to be low [25, 26]. This may
account for the sustained expression of stromal fibro-
blast activation markers in tendon tissues from patients
up to 4 years after treatment in both symptomatic and
asymptomatic patients.
In our previous work investigating inflammation in cul-
tured stromal cells derived from diseased human tendons,
we proposed that diseased cells may be primed for inflam-
mation [8]. In the current study, we identified IL-1β-
treated diseased tendon cells showed a more profound
induction of PDPN and CD106 and sustained expression
of IL6 and IL8 mRNA compared to IL-1β-treated healthy
tendon cells. Our findings support the concept that
diseased tendon cells previously exposed to inflammation
are primed and become hyper-responsive on subsequent
exposure, possessing “stromal memory”. In support of this,
Fig. 7 Isotype control staining of diseased human supraspinatus tendons. a, b Representative bright field images of diseased tendon sections
stained with isotype control antibodies for mouse IgG1, IgG2a, IgG2b and rabbit IgG fractions. Nuclear counterstain is haematoxylin. Scale bar
50 μm. c, d Representative confocal immunofluorescence images showing merged image of diseased tendon sections stained with isotype
control antibodies for mouse IgG1, IgG2a, IgG2b and rabbit IgG fractions. Cyan represents POPO-1 nuclear counterstain. Scale bar 20 μm
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studies of cancer-associated fibroblasts [27, 28] and of syn-
ovial fibroblasts in RA [9, 10] emphasize the important
contribution of resident stromal cell populations to the
persistence of chronic inflammation. Epigenetic changes in
stromal cell populations are thought to be implicated in
fibroblast activation. Changes in the epigenome can modu-
late the inflammatory response and promote the develop-
ment of chronic disease [29].
Diseased tendon tissues investigated in the current
study were collected from patients undergoing sub-
acromial decompression surgery or surgical debridement
of a supraspinatus tendon tear ranging from small
(<1 cm) to massive (>5 cm) in size. Patients with large
to massive tendon tears likely represent the end stage of
the disease spectrum. Stromal fibroblast activation
markers were highly expressed in all tendinopathic and
torn tissues investigated in this study. We recently
identified the plasticity and complexity of inflammation
activation signatures in diseased human shoulder ten-
dons [8]. The current study using tissues from these
same patient cohorts demonstrated that markers of stro-
mal fibroblast activation are highly expressed in diseased
tendons, and that disease stage does not influence the
degree of expression of PDPN, CD106 and CD248.
These findings further support the concept of stromal
fibroblast “memory” and suggest that exposure of tendon
cells to an inflammatory stimulus induces a sustained
change in their phenotype.
Repetitive damage through cumulative loading is a
known contributor to the development of tendon dis-
ease. Mechanical cues can also induce tendon cells and
tissues to release pro-inflammatory mediators including
prostaglandins and pro-inflammatory cytokines [30, 31].
The effects of mechanical loading on stromal activation
in tendinopathy have not been directly investigated.
However, it is conceivable that in a disease setting, both
mechanical and chemical cues may potentially induce
stromal fibroblast activation as both stimuli possess the
capacity to induce inflammation.
We acknowledge there are potential limitations with
the use of hamstring tendons as a comparator to
diseased tendons, including tendon type and age differ-
ences. However, hamstring tendon was taken from live
healthy donors without history of tendinopathy. We
believe this is a more suitable comparator than cadaveric
shoulder tendon tissues, where little is known about
whether the tendons were healthy or diseased or whether
tendons were affected by post mortem changes.
Conclusions
The findings from this study support the important and
sustained contribution of diseased tendon stromal cells
to the development and persistence of non-resolving
tendon inflammation. We showed for the first time that
stromal fibroblast activation markers are increased in
diseased compared to healthy human tendon tissues and
cells and identified distinct stromal responses in diseased
tendons. We demonstrated that inflammation induces
stromal fibroblast activation and stromal “memory”,
which is more profound in diseased compared to healthy
tendon cells. We propose that persistent stromal fibro-
blast activation is an important mechanism for the de-
velopment of chronic inflammation and recurrent
tendinopathy. Targeting activated tendon stromal cells is
a potential therapeutic strategy for curative intervention.
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